These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 28786057)
61. K356dup--an in-frame insertion in the BCR-ABL gene in an imatinib-resistant chronic myeloid leukemia. Gniot M; Wasilewska EM; Lewandowski K Int J Lab Hematol; 2012 Dec; 34(6):e3-6. PubMed ID: 25998099 [No Abstract] [Full Text] [Related]
62. Differential expression and alternative splicing of cell cycle genes in imatinib-treated K562 cells. Liu J; Lin J; Huang LF; Huang B; Xu YM; Li J; Wang Y; Zhang J; Yang WM; Min QH; Wang XZ Tumour Biol; 2015 Sep; 36(10):8127-36. PubMed ID: 25983000 [TBL] [Abstract][Full Text] [Related]
63. Blockade of the interaction between Bcr-Abl and PTB1B by small molecule SBF-1 to overcome imatinib-resistance of chronic myeloid leukemia cells. Elgehama A; Chen W; Pang J; Mi S; Li J; Guo W; Wang X; Gao J; Yu B; Shen Y; Xu Q Cancer Lett; 2016 Mar; 372(1):82-8. PubMed ID: 26721204 [TBL] [Abstract][Full Text] [Related]
64. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy. Ferri C; Bianchini M; Bengió R; Larripa I Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144 [TBL] [Abstract][Full Text] [Related]
65. Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment. Oaxaca DM; Yang-Reid SA; Ross JA; Rodriguez G; Staniswalis JG; Kirken RA Tumour Biol; 2016 Sep; 37(9):12643-12654. PubMed ID: 27444277 [TBL] [Abstract][Full Text] [Related]
66. miR-101 sensitizes K562 cell line to imatinib through Jak2 downregulation and inhibition of NF-κB target genes. Farhadi E; Zaker F; Safa M; Rezvani MR Tumour Biol; 2016 Oct; 37(10):14117-14128. PubMed ID: 27517565 [TBL] [Abstract][Full Text] [Related]
67. Circ_0009910 promotes imatinib resistance through ULK1-induced autophagy by sponging miR-34a-5p in chronic myeloid leukemia. Cao HX; Miao CF; Sang LN; Huang YM; Zhang R; Sun L; Jiang ZX Life Sci; 2020 Feb; 243():117255. PubMed ID: 31923418 [TBL] [Abstract][Full Text] [Related]
68. microRNA-199a/b-5p enhance imatinib efficacy via repressing WNT2 signaling-mediated protective autophagy in imatinib-resistant chronic myeloid leukemia cells. Chen PH; Liu AJ; Ho KH; Chiu YT; Anne Lin ZH; Lee YT; Shih CM; Chen KC Chem Biol Interact; 2018 Aug; 291():144-151. PubMed ID: 29890129 [TBL] [Abstract][Full Text] [Related]
69. Overexpression of RPS27a contributes to enhanced chemoresistance of CML cells to imatinib by the transactivated STAT3. Wang H; Xie B; Kong Y; Tao Y; Yang G; Gao M; Xu H; Zhan F; Shi J; Zhang Y; Wu X Oncotarget; 2016 Apr; 7(14):18638-50. PubMed ID: 26942564 [TBL] [Abstract][Full Text] [Related]
70. Identification and functional characterization of the miRNA-gene regulatory network in chronic myeloid leukemia lineage negative cells. Agatheeswaran S; Pattnayak NC; Chakraborty S Sci Rep; 2016 Sep; 6():32493. PubMed ID: 27586591 [TBL] [Abstract][Full Text] [Related]
71. Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells. Lu Y; Liu LL; Liu SS; Fang ZG; Zou Y; Deng XB; Long ZJ; Liu Q; Lin DJ J Transl Med; 2016 Sep; 14():270. PubMed ID: 27645552 [TBL] [Abstract][Full Text] [Related]
72. Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms. Lan X; Zhao C; Chen X; Zhang P; Zang D; Wu J; Chen J; Long H; Yang L; Huang H; Carter BZ; Wang X; Shi X; Liu J J Hematol Oncol; 2016 Nov; 9(1):129. PubMed ID: 27884201 [TBL] [Abstract][Full Text] [Related]
73. The second generation of BCR-ABL tyrosine kinase inhibitors. Tauchi T; Ohyashiki K Int J Hematol; 2006 May; 83(4):294-300. PubMed ID: 16757427 [TBL] [Abstract][Full Text] [Related]
74. Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL. Aljedai A; Buckle AM; Hiwarkar P; Syed F PLoS One; 2015; 10(4):e0123016. PubMed ID: 25849484 [TBL] [Abstract][Full Text] [Related]
75. Knock-down of CIAPIN1 sensitizes K562 chronic myeloid leukemia cells to Imatinib by regulation of cell cycle and apoptosis-associated members via NF-κB and ERK5 signaling pathway. Wang J; Li Q; Wang C; Xiong Q; Lin Y; Sun Q; Jin H; Yang F; Ren X; Pang T Biochem Pharmacol; 2016 Jan; 99():132-45. PubMed ID: 26679828 [TBL] [Abstract][Full Text] [Related]
76. Induction of apoptosis in imatinib sensitive and resistant chronic myeloid leukemia cells by efficient disruption of bcr-abl oncogene with zinc finger nucleases. Huang N; Huang Z; Gao M; Luo Z; Zhou F; Liu L; Xiao Q; Wang X; Feng W J Exp Clin Cancer Res; 2018 Mar; 37(1):62. PubMed ID: 29554925 [TBL] [Abstract][Full Text] [Related]
77. Perturbation of energy metabolism by fatty-acid derivative AIC-47 and imatinib in BCR-ABL-harboring leukemic cells. Shinohara H; Kumazaki M; Minami Y; Ito Y; Sugito N; Kuranaga Y; Taniguchi K; Yamada N; Otsuki Y; Naoe T; Akao Y Cancer Lett; 2016 Feb; 371(1):1-11. PubMed ID: 26607903 [TBL] [Abstract][Full Text] [Related]
78. CD-200 induces apoptosis and inhibits Bcr-Abl signaling in imatinib-resistant chronic myeloid leukemia with T315I mutation. Fang Z; Jung KH; Yan HH; Kim SJ; Son MK; Rumman M; Lee H; Kim KW; Yoo HD; Hong SS Int J Oncol; 2015 Jul; 47(1):253-61. PubMed ID: 25963192 [TBL] [Abstract][Full Text] [Related]
79. Revealing genome-wide mRNA and microRNA expression patterns in leukemic cells highlighted "hsa-miR-2278" as a tumor suppressor for regain of chemotherapeutic imatinib response due to targeting STAT5A. Kaymaz BT; Günel NS; Ceyhan M; Çetintaş VB; Özel B; Yandım MK; Kıpçak S; Aktan Ç; Gökbulut AA; Baran Y; Can BK Tumour Biol; 2015 Sep; 36(10):7915-27. PubMed ID: 25953263 [TBL] [Abstract][Full Text] [Related]
80. Prevalence of BCR-ABL T315I Mutation in Malaysian Patients with Imatinib-Resistant Chronic Myeloid Leukemia. Mat Yusoff Y; Abu Seman Z; Othman N; Kamaluddin NR; Esa E; Zulkiply NA; Abdullah J; Zakaria Z Asian Pac J Cancer Prev; 2018 Dec; 19(12):3317-3320. PubMed ID: 30583336 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]